Agilent Technologies Inc. has introduced SurePrint G3 CGH+SNP cancer catalog microarrays, addressing the growing need of researchers to detect both copy number and copy-neutral aberrations in cancer ...
Three Cancer Genome Characterization Centers Select Agilent’s Microarray Platform to Profile Cancers
The National Cancer Institute (NCI) has announced grant recipients for its coveted Cancer Genome Atlas pilot project, including three institutions using microarray platforms from Agilent Technologies ...
Protein detection and quantification are daily occurrences both in research and diagnostic laboratories. Also, follow-ups of therapeutic treatments and prognoses have grown to rely more and more on ...
A novel dosing schedule with gemcitabine, vinorelbine, and carboplatin for advanced non-small cell cancer of the lung No significant financial relationships to disclose. This is an ASCO Meeting ...
Pancreatic cancer is the fifth leading cause of death in the United States with approximately 28,000 deaths/year. Notwithstanding all the efforts, it is still one of the most difficult cancers to ...
In the post-genomic era, long non-coding RNAs (lncRNAs) have emerged as critical regulators in various cancers and hold potential as minimally invasive diagnostic biomarkers. This study aimed to ...
Expression patterns for 7 and 20 genes that were selected as discriminators of relapse versus continuous complete remission (CCR) for two types of acute lymphoblastic leukemia, T-ALL and hyperdiploid ...
Determining true HER2 status in breast cancers with polysomy using alternative chromosome 17 reference genes: Implications for trastuzumab therapy. Background: Systemic chemo- and chemoradiation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results